Lifecore Biomedical
LFCR
90 hedge funds and large institutions have $367M invested in Lifecore Biomedical in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 38 increasing their positions, 19 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 19
1.56% more ownership
Funds ownership: 90.98% → 92.54% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $374M → $367M (-$6.53M)
2% less funds holding
Funds holding: 92 → 90 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICOM
Investment Counselors of Maryland
Baltimore,
Maryland
|
+$2.56M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$1.7M |
| 3 |
RA
Royce & Associates
New York
|
+$1.65M |
| 4 |
Renaissance Technologies
New York
|
+$1.2M |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
+$882K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$4.81M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$4.46M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.55M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.62M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$1.17M |
LFCR Hedge Fund Activity: Q3 2018 in Review
90 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2018, worth a combined $367M — down 1.7% from $374M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LFCR and 10 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 38 added.
The largest buyer was Investment Counselors of Maryland, adding an estimated $2.56M. The largest seller was Ariel Investments, exiting entirely with an estimated $4.81M sold.
- 90 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2018, down from 92 in Q2 2018.
- Funds reported $367M of Lifecore Biomedical stock for Q3 2018, down 1.7% quarter-over-quarter.
- 10 funds opened new Lifecore Biomedical positions in Q3 2018 and 12 closed out, a net change of -2 holders.
- The largest Lifecore Biomedical buyer in Q3 2018 was Investment Counselors of Maryland, an estimated $2.56M added.
- The largest Lifecore Biomedical seller in Q3 2018 was Ariel Investments, an estimated $4.81M sold.
Based on aggregated 13F filings for Q3 2018.